

1 **ACZONE™ Gel 5% PACKAGE INSERT**


2  
3 **ACZONE™ (dapson) Gel, 5%**

4 FOR TOPICAL USE ONLY

5 NOT FOR ORAL, OPHTHALMIC, OR INTRAVAGINAL USE

6  
7  
8 **DESCRIPTION**

9  
10 ACZONE™ Gel, 5%, contains dapsone, a sulfone, in an aqueous gel base for topical  
11 dermatologic use. ACZONE™ Gel is a gritty, translucent material with visible drug  
12 substance particles. Chemically, dapsone has an empirical formula of C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>S. It is  
13 a white, odorless crystalline powder that has a molecular weight of 248. Dapsone's  
14 chemical name is 4,4'-diaminodiphenylsulfone and its structural formula is:



15  
16 Each gram of ACZONE™ (dapson) Gel, 5%, contains 50 mg of dapsone, USP, in a gel  
17 of carbomer 980; diethylene glycol monoethyl ether, NF; methylparaben, NF; sodium  
18 hydroxide, USP; and purified water, USP.

19  
20  
21 **CLINICAL PHARMACOLOGY**

22  
23 **Mechanism of Action:**

24 The mechanism of action of dapsone gel in treating acne vulgaris is not known.

25  
26 **Pharmacokinetics:**

27 An open-label study compared the pharmacokinetics of dapsone after ACZONE™ Gel,  
28 5%, (110 ± 60 mg/day) was applied twice daily (~BSA 22.5%) for 14 days (n=18) with a  
29 single 100 mg dose of oral dapsone administered to a subgroup of patients (n=10) in a  
30 crossover design. On Day 14 the mean dapsone AUC<sub>0-24 h</sub> was 415 ± 224 ng•h/mL for  
31 ACZONE™ Gel, 5%, whereas following a single 100 mg dose of oral dapsone the AUC<sub>0-  
32 infinity</sub> was 52,641 ± 36,223 ng•h/mL.

33  
34 **Special Populations:** In a clinical study, periodic blood samples were collected up to 12  
35 months to determine systemic exposure of dapsone and its metabolites in approximately  
36 500 patients. Based on the measurable dapsone concentrations from 408 patients  
37 (M=192, F=216), obtained at month 3, neither gender, nor race appeared to affect the  
38 pharmacokinetics of dapsone. Similarly, dapsone exposures were approximately the  
39 same between the age groups of 12-15 years (N=155) and those greater than or equal to  
40 16 years (N=253).

42 **MICROBIOLOGY**

43

44 In Vivo Activity: No microbiology or immunology studies were conducted during  
45 dapsons gel clinical trials.

46

47 Drug Resistance: No dapsons resistance studies were conducted during dapsons gel  
48 clinical trials. Therapeutic resistance to dapsons has been reported for *Mycobacterium*  
49 *leprae*, when patients have been treated with oral dapsons.\*

50

51 \*Matsuoka, M. A. Dec 2000. *Mycobacterium leprae* isolate resistant to dapsons, rifampin, ofloxacin and  
52 sparfloracin. Int J Lepr Other Mycobact Dis. 68(4):452-5.

53

54

55 **CLINICAL STUDIES**

56

57 Two randomized, double blind, vehicle controlled, clinical studies were conducted to  
58 evaluate ACZONE™ Gel, 5%, for the treatment of patients with acne vulgaris (N=1475  
59 and 1525). The studies were designed to enroll patients 12 years of age and older with 20  
60 to 50 inflammatory and 20 to 100 non-inflammatory lesions at baseline. In these studies  
61 patients applied either ACZONE™ Gel, 5%, or vehicle control twice daily for up to 12  
62 weeks. Efficacy was evaluated in terms of success on the Global Acne Assessment  
63 Score (no or minimal acne) and in the percent reduction in inflammatory, non-  
64 inflammatory, and total lesions.

65

66 The Global Acne Assessment Score was a 5-point scale as follows:

67

- 68 0 None: no evidence of facial acne vulgaris
- 69 1 Minimal: few non-inflammatory lesions (comedones) are present; a few  
70 inflammatory lesions (papules/pustules) may be present
- 71 2 Mild: several to many non-inflammatory lesions (comedones) are present;  
72 a few inflammatory lesions (papules/pustules) are present
- 73 3 Moderate: many non-inflammatory (comedones) and inflammatory lesions  
74 (papules/pustules) are present; no nodulo-cystic lesions are allowed
- 75 4 Severe: significant degree of inflammatory disease; papules/pustules are a  
76 predominant feature; a few nodulo-cystic lesions may be present;  
77 comedones may be present.

77

78 The success rates on the Global Acne Assessment Score (no or minimal acne) at Week 12  
79 are presented in Table 1.

80

81

Table 1 - Success (No or Minimal Acne) on the Global Acne Assessment Score at Week 12

	Study 1*		Study 2*	
	ACZONE™ N=699	Vehicle N=687	ACZONE™ N=729	Vehicle N=738
Subjects with No or Minimal Acne	291 (42%)	223 (32%)	253 (35%)	206 (28%)

82

\*Analysis excludes subjects classified with minimal acne at baseline

83  
84  
85  
86  
87

Table 2 presents the mean percent reduction in inflammatory, non-inflammatory, and total lesions from baseline to Week 12.

Table 2 - Percent Reduction in Lesions from Baseline to Week 12

	Study 1		Study 2	
	ACZONE™ N=745	Vehicle N=740	ACZONE™ N=761	Vehicle N=764
Inflammatory	46%	42%	48%	40%
Non-Inflammatory	31%	24%	30%	21%
Total	38%	32%	37%	29%

88  
89  
90  
91  
92  
93  
94  
95

The clinical studies enrolled about equal proportions of male and female subjects. Female patients tended to have greater percent reductions in lesions and greater success on the Global Acne Assessment Score than males. The breakdown by race in the clinical studies was about 73% Caucasian, 14% Black, 9% Hispanic, and 2% Asian. Efficacy results were similar across the racial subgroups.

## INDICATIONS AND USAGE

96  
97  
98  
99

ACZONE™ Gel, 5%, is indicated for the topical treatment of acne vulgaris.

Glucose 6-phosphate dehydrogenase (G6PD) levels should be obtained prior to initiating therapy with ACZONE™ Gel, 5%. In patients with a history of anemia and predisposition to increased hemolytic effect with dapsone (e.g., glucose-6-phosphate dehydrogenase deficiency), closer follow-up for blood hemoglobin levels and reticulocyte counts should be implemented (see PRECAUTIONS). Alternatively, other therapies for acne than ACZONE™ Gel, 5%, may be considered.

106  
107

## CONTRAINDICATIONS

108  
109  
110  
111  
112

ACZONE™ Gel, 5%, is contraindicated in persons with a hypersensitivity to dapsone or any other component of the formulation.

113  
114

## PRECAUTIONS

115  
116  
117

### General

Glucose 6-phosphate dehydrogenase levels should be obtained in all patients prior to initiating therapy with ACZONE™ Gel, 5%. Baseline complete blood counts, including a reticulocyte count, should be obtained in patients who are G6PD deficient or with a history of anemia. Routine follow-up for complete blood count and reticulocyte count

122 should be implemented for patients at risk. If signs, symptoms or laboratory evidence of  
123 anemia develop during treatment, use of ACZONE™ Gel, 5%, should be discontinued.  
124 Dose-related hemolysis is the most common adverse event seen in patients treated with  
125 oral Dapsone (with or without glucose-6-phosphate dehydrogenase deficiency).  
126 Hemolysis may be exaggerated in individuals with G6PD deficiency, methemoglobin  
127 reductase deficiency, or hemoglobin M.

128  
129 While clinical studies conducted did not demonstrate evidence of clinically significant  
130 anemia, an increased reticulocyte count and a decreased hemoglobin level were noted to  
131 be associated in a G6PD deficient patient treated with ACZONE™ Gel, 5%, for acne  
132 vulgaris who had a complete blood count performed. Only 25 patients with low plasma  
133 glucose 6-phosphate dehydrogenase activity treated with ACZONE™ Gel, 5%, were  
134 included in the clinical study program. Safety of ACZONE™ Gel, 5%, has not been  
135 fully evaluated in patients with G6PD deficiency.

136  
137 Although not observed in the clinical trials with topical dapsone, serious adverse  
138 reactions have been reported with oral use of dapsone, including agranulocytosis,  
139 hemolytic anemia, peripheral neuropathy (motor loss and muscle weakness), and skin  
140 reactions (toxic epidermal necrolysis, erythema multiforme, morbilliform and  
141 scarlatiniform reactions, bullous and exfoliative dermatitis, erythema nodosum, and  
142 urticaria).

143  
144 In the clinical trials, a total of 12 out of 4032 patients were reported to have depression (3  
145 of 1660 treated with vehicle and 9 of 2372 treated with ACZONE™ Gel, 5%). Psychosis  
146 was reported in 2 of 2372 patients treated with ACZONE™ Gel, 5%, and in 0 of 1660  
147 patients treated with vehicle.

#### 148 149 **Information for Patients**

- 150
- 151 1. Patients should use ACZONE™ Gel, 5%, as directed by the physician. ACZONE™  
152 Gel, 5%, is for external topical use only. ACZONE™ Gel, 5%, is not for oral,  
153 ophthalmic or intravaginal use.
  - 154 2. Patients should not use this medication for any disorder other than that for which it  
155 was prescribed.
  - 156 3. Patients should tell their physician if they have any history of anemia or an enzyme  
157 deficiency (such as G6PD deficiency).
  - 158 4. Patients should be informed as to the need for laboratory evaluation prior to starting  
159 ACZONE™ Gel, 5%.
  - 160 5. Patients should report any signs of adverse reactions to their physician.
  - 161 6. Protect ACZONE™ Gel, 5%, from freezing and light. Return to the original carton  
162 after application to protect from light.
  - 163 7. See Patient Information for additional information on safety, efficacy, general use,  
164 and storage of ACZONE™ Gel, 5%.

#### 165 **Laboratory Tests**

166

167 Glucose 6-phosphate dehydrogenase levels should be obtained in all patients prior to  
168 initiating therapy with ACZONE™ Gel, 5%. Baseline complete blood counts, including  
169 a reticulocyte count, should be obtained in patients who are G6PD deficient or with a  
170 history of anemia. Routine follow-up for complete blood count and reticulocyte count  
171 should be implemented for patients at risk.

172

### 173 **Drug Interactions**

174 A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in  
175 combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole  
176 (TMP/SMX). During co-administration, systemic levels of TMP and SMX were  
177 essentially unchanged. However, levels of dapsone and its metabolites increased in the  
178 presence of TMP/SMX. Systemic exposure (AUC<sub>0-12</sub>) of dapsone and N-acetyl-dapsone  
179 (NAD) were increased by about 40% and 20% respectively in presence of TMP/SMX.  
180 Notably, systemic exposure (AUC<sub>0-12</sub>) of dapsone hydroxylamine (DHA) was more than  
181 doubled in the presence of TMP/SMX. Exposure from the proposed topical dose is about  
182 1% of that from the 100 mg oral dose, even when co-administered with TMP/SMX.

183

184 Certain concomitant medications (such as rifampin, anticonvulsants, St. John's wort) may  
185 increase the formation of dapsone hydroxylamine, a metabolite of dapsone associated  
186 with hemolysis. With oral dapsone treatment, folic acid antagonists such as  
187 pyrimethamine have been noted to possibly increase the likelihood of hematologic  
188 reactions.

189

### 190 **Carcinogenesis, Mutagenesis, Impairment of Fertility**

191

192 Dapsone was not mutagenic in a bacterial reverse mutation assay (Ames test) using  
193 *S. typhimurium* and *E. coli*, with and without metabolic activation and was negative in a  
194 micronucleus assay conducted in mice. Dapsone increased both numerical and structural  
195 aberrations in a chromosome aberration assay conducted with Chinese hamster ovary  
196 (CHO) cells.

197

198 In studies conducted for ACZONE Gel, 5%, dapsone was not carcinogenic to rats when  
199 orally administered to females for 92 weeks or males for 100 weeks at dose levels up to  
200 15 mg/kg/day (approximately 160 times the systemic exposure observed in human males  
201 and 300 times the systemic exposure observed in human females as a result of use of the  
202 maximum recommended topical dose, based on AUC comparisons).

203

204 No evidence of potential to induce carcinogenicity was obtained in a dermal study in  
205 which dapsone gel was topically applied to Tg.AC transgenic mice for approximately 26  
206 weeks. Dapsone concentrations of 3%, 5%, and 10% were evaluated; 3% material was  
207 judged to be the maximum tolerated dosage.

208

209 ACZONE Gel, 5%, did not increase the rate of formation of ultra violet light-induced  
210 skin tumors when topically applied to hairless mice in a 12-month photocarcinogenicity  
211 study.

212

213 The effects of dapsone on fertility and general reproduction performance were assessed in  
214 male and female rats following oral (gavage) dosing. Dapsone reduced sperm motility at  
215 dosages of 3 mg/kg/day or greater (approximately 17 times the systemic exposure  
216 observed in human males as a result of use of the maximum recommended topical dose,  
217 based on AUC comparisons). The mean numbers of embryo implantations and viable  
218 embryos were significantly reduced in untreated females mated with males that had been  
219 dosed at 12 mg/kg/day or greater (approximately 70 times the systemic exposure  
220 observed in human males as a result of use of the maximum recommended topical dose,  
221 based on AUC comparisons), presumably due to reduced numbers or effectiveness of  
222 sperm, indicating impairment of fertility. Dapsone had no effect on male fertility at  
223 dosages of 2 mg/kg/day or less (approximately 13 times the systemic exposure observed  
224 in human males as a result of use of the maximum recommended topical dose, based on  
225 AUC comparisons). When administered to female rats at a dosage of 75 mg/kg/day  
226 (approximately 800 times the systemic exposure observed in human females as a result of  
227 use of the maximum recommended topical dose, based on AUC comparisons) for 15 days  
228 prior to mating and for 17 days thereafter, dapsone reduced the mean number of  
229 implantations, increased the mean early resorption rate, and reduced the mean litter size.  
230 These effects were probably secondary to maternal toxicity.

231

232 Dapsone was assessed for effects on perinatal/postnatal pup development and postnatal  
233 maternal behavior and function in a study in which dapsone was orally administered to  
234 female rats daily beginning on the seventh day of gestation and continuing until the  
235 twenty-seventh day postpartum. Maternal toxicity (decreased body weight and food  
236 consumption) and developmental effects (increase in stillborn pups and decreased pup  
237 weight) were seen at a dapsone dose of 30 mg/kg/day (approximately 500 times the  
238 systemic exposure observed in human females as a result of use of the maximum  
239 recommended topical dose, based on AUC comparisons). No effects were observed on  
240 the viability, physical development, behavior, learning ability, or reproductive function of  
241 surviving pups.

242

### 243 **Pregnancy:**

### 244 **Teratogenic Effects: Pregnancy Category C**

245

246 Dapsone has been shown to have an embryocidal effect in rats and rabbits when given in  
247 doses of 75 mg/kg/day and 150 mg/kg/day (approximately 800 and 500 times the  
248 systemic exposure observed in human females as a result of use of the maximum  
249 recommended topical dose, based on AUC comparisons), respectively. These effects  
250 were probably secondary to maternal toxicity. There are no adequate and well controlled  
251 studies in pregnant women. ACZONE Gel, 5%, should be used during pregnancy only if  
252 the potential benefit justifies the potential risk to the fetus.

253

### 254 **Nursing Mothers:**

255

256 Although systemic absorption of dapsone following topical application of ACZONE™  
257 Gel, 5%, is minimal relative to oral dapsone administration, it is known that dapsone is  
258 excreted in human milk. Because of the potential for oral dapsone to cause adverse

259 reactions in nursing infants, a decision should be made whether to discontinue nursing or  
260 to discontinue ACZONE™ Gel, 5%, taking into account the importance of the drug to the  
261 mother.

262

263 **Pediatric Use:**

264

265 Safety and efficacy was evaluated in 1169 children aged 12-17 years old treated with  
266 ACZONE Gel, 5%, in the clinical studies. The adverse event rate for ACZONE™ Gel,  
267 5%, was similar to the vehicle control group. Safety and efficacy was not studied in  
268 pediatric patients less than 12 years of age, therefore ACZONE™ Gel, 5%, is not  
269 recommended for use in this age group.

270

271 **Geriatric Use:**

272

273 Clinical studies of ACZONE™ Gel, 5%, did not include sufficient number of patients  
274 aged 65 and over to determine whether they respond differently from younger patients.

275

276

277 **ADVERSE REACTIONS**

278

279 While clinical studies conducted with ACZONE Gel, 5%, for acne vulgaris did not  
280 demonstrate evidence of clinically significant anemia, an increased reticulocyte count and  
281 a decreased hemoglobin level were found in a G6PD deficient patient who had a  
282 complete blood count performed. Only 25 patients with low plasma glucose 6-phosphate  
283 dehydrogenase activity treated with ACZONE Gel, 5%, were included in the clinical  
284 study program.

285

286 Serious adverse events reported in patients treated with ACZONE Gel, 5%, during  
287 clinical trials included but were not limited to the following:

288 Nervous system/Psychiatric – Suicide attempt, tonic clonic movements.

289 Gastrointestinal – Abdominal pain, severe vomiting, pancreatitis.

290 Other – Severe pharyngitis

291

292 Combined contact sensitization/irritation studies with ACZONE Gel, 5%, in 253 healthy  
293 subjects resulted in at least 3 subjects with moderate erythema. ACZONE™ Gel, 5%,  
294 did not induce phototoxicity or photoallergy in human dermal safety studies.

295

296 ACZONE™ Gel, 5%, was evaluated for 12 weeks in four controlled studies for local  
297 cutaneous events in 1819 patients. The most common events reported from these studies  
298 include oiliness/peeling, dryness, and erythema. These data are shown by severity in  
299 Table 3 below.

300

301 Table 3 - Application Site Adverse Events by Maximum Severity from Four 12-Week, Vehicle-Controlled  
 302 Studies

Application Site Event	ACZONE™ (N=1819)			Vehicle (N=1660)		
	Mild	Moderate	Severe	Mild	Moderate	Severe
Erythema	9%	5%	<1%	9%	6%	<1%
Dryness	14%	3%	<1%	14%	4%	<1%
Oiliness/Peeling	13%	6%	<1%	15%	6%	<1%

303  
 304 There were no significant differences in the adverse event rates between ACZONE™  
 305 Gel, 5%, and vehicle control treated patients. The adverse events occurring in at least 1%  
 306 of patients in either arm in the four vehicle controlled studies are presented in Table 4.  
 307

308 Table 4 – Adverse Events Occurring in at least 1% of Patients in Four Vehicle Controlled Studies

	ACZONE™ N=1819	Vehicle N=1660
Application Site Reaction NOS	18%	20%
Application Site Dryness	16%	17%
Application Site Erythema	13%	14%
Application Site Burning	1%	2%
Application Site Pruritus	1%	1%
Pyrexia	1%	1%
Nasopharyngitis	5%	6%
Upper Respiratory Tract Inf. NOS	3%	3%
Sinusitis NOS	2%	1%
Influenza	1%	1%
Pharyngitis	2%	2%
Cough	2%	2%
Joint Sprain	1%	1%
Headache NOS	4%	4%

309  
 310 One patient treated with topical dapsone in the clinical trials had facial swelling which  
 311 led to discontinuation of medication.  
 312

313 In addition, 486 patients were evaluated in a 12 month safety study. The adverse event  
 314 profile in this study was consistent with that observed in the vehicle-controlled studies.  
 315

316  
 317 **OVERDOSAGE**  
 318

319 ACZONE™ Gel, 5%, is not for oral use. If oral ingestion occurs, medical advice should  
 320 be sought.  
 321

322 **DOSAGE AND ADMINISTRATION**  
 323

324 After the skin is gently washed and patted dry, apply approximately a pea-sized amount  
325 of ACZONE™ Gel, 5%, in a thin layer to the acne affected areas twice daily. Rub in  
326 ACZONE™ Gel, 5%, gently and completely. ACZONE™ Gel, 5%, is gritty with visible  
327 drug substance particles present. Wash hands after application of ACZONE™ Gel, 5%.

328

329 If there is no improvement after 12 weeks, appropriateness of treatment with ACZONE™  
330 Gel, 5%, should be reassessed.

331

332

333 **HOW SUPPLIED:**

334

335 ACZONE™ (dapson) Gel, 5%, is supplied in the following size tubes:

336

337 Professional Sample

338 5 % NDC 0469-5005-03      Product Code 500503

339 3 gram laminate tube

340

341 Commercially Available as:

342 5 % NDC 0469-5005-30      Product Code 500530

343 30 gram plastic tube

344

345 **KEEP OUT OF THE REACH OF CHILDREN LESS THAN 12 YEARS OLD.**

346

347 Storage conditions:

348 Store at controlled room temperature, 20-25 °C (68-76 °F), excursions permitted to 15–  
349 30 °C (59–86 °F). Protect from freezing and light. Return to the original carton after  
350 application.

351

352 Rx Only

353

354 Manufactured by QLT USA, Inc., Fort Collins, CO 80525

355

356

357 **PATIENT INFORMATION**

358

359

ACZONE™ (dapsone) Gel 5%

360

361 Read this important information before you start using ACZONE™ (AK-zōn) Gel and  
362 each time you refill your prescription. There may be new information that you need to  
363 know. This summary is not meant to take the place of your doctor's advice. If you have  
364 any questions or want more information about ACZONE™ Gel, ask your doctor or  
365 pharmacist.

366

367 ***What is ACZONE™ Gel?***

368 ACZONE™ Gel is a prescription skin use (topical) medicine used to help treat acne in  
369 people 12 years and older.

370

371 ACZONE™ Gel has not been studied in children under 12 years of age.

372

373 ***Who should not use ACZONE™ Gel?***

374 Do not use ACZONE™ Gel if you are allergic any of the ingredients in ACZONE™  
375 Gel. Ask your doctor or pharmacist for a list of these ingredients. The active ingredient  
376 is dapsone. See the end of this leaflet for a complete list of ingredients in ACZONE™  
377 Gel.

378

379 ***What should I tell my doctor before using ACZONE™ Gel?***

380 **Tell your doctor about all of your medical conditions, including if you:**

- 381 • are pregnant or planning to become pregnant. It is not known if ACZONE Gel  
382 may harm your unborn baby.
- 383 • are breastfeeding. ACZONE™ Gel passes into your milk and may harm your  
384 baby. You should choose either to use ACZONE™ Gel, or breastfeed, but not  
385 both. Talk to you doctor about the best way to feed your baby while using  
386 ACZONE™ Gel.
- 387 • have a history of anemia or have been diagnosed with glucose-6-phosphate  
388 dehydrogenase deficiency

389

390 **Tell your doctor about all the medicines you are taking including prescription and**  
391 **nonprescription medicines, vitamins and herbal supplements.** Especially, tell your  
392 doctor if you are using any other medicines applied to the skin.

393

394 ***How do I use ACZONE™ Gel?***

- 395 • Use ACZONE™ Gel exactly as prescribed by your doctor. ACZONE™ Gel is  
396 usually used on your affected skin twice a day, once in the morning and once in the  
397 evening.
- 398 • Wash the areas of your skin where you will apply ACZONE™ Gel. Gently pat your  
399 skin dry with a clean towel.
- 400 • Apply a thin layer of ACZONE™ Gel to the areas of your skin that have acne. A pea-  
401 sized amount of ACZONE™ Gel will usually be enough.

- 402 • Rub the medicine in gently and completely  
403 • Make sure to put the cap back on the ACZONE™ Gel tube. Close it tightly and put  
404 the tube back in its original box.  
405 • Wash your hands after applying ACZONE™ Gel.  
406 • Keep ACZONE™ Gel away from your mouth and eyes. Do not swallow  
407 ACZONE™ Gel. If you swallow ACZONE™ Gel, call your doctor or poison control  
408 center right away.  
409 • If your acne does not get better after using ACZONE™ for 12 weeks, talk to your  
410 doctor about other treatments for acne.

411

#### 412 *What are the possible side effects of ACZONE™ Gel?*

413 Like all medicines, ACZONE™ Gel can cause some side effects. These side effects are  
414 usually mild. The most common side effects of ACZONE™ Gel are dryness, redness,  
415 oiliness and peeling of the skin being treated.

416 Call your doctor if you have excessive tiredness or any side effects that do not go away or  
417 bother you. This is not a complete list of all the side effects. If you have any questions,  
418 ask your doctor or pharmacist.

419

#### 420 *How should I store ACZONE™ Gel?*

421 Store ACZONE™ Gel at room temperature 68 to 76 °F. Do not freeze ACZONE™ Gel.  
422 Protect ACZONE™ Gel tube from light. Store in original box after using it.

423

424 Keep ACZONE™ Gel out of the reach of children less than 12 years of age.

425

#### 426 *Where can I find more information about ACZONE™ Gel?*

427 If you have any questions or want more information about ACZONE™ Gel, ask your  
428 doctor or pharmacist. Your doctor or pharmacist can also give you a copy of the  
429 ACZONE™ Gel Package Insert written for health professionals. Ask them to explain  
430 anything you do not understand.


431

432 You may call 1-800-727-7003 to obtain more information about ACZONE™ Gel.

433

434

435



PMS265C


Black

Astellas logo

Red: 193C

Gray Cool gray 9C

Overlap: 193C + Cool Gray 9C (40%)



CrossTech-46871-Proof A9  
 Form M01  
 Astellas Pharma US, Inc.-P.O. 21321-Job No. 02110  
 6/30/05-am-Q4.1

Fonts: Helvetica (A)  
 Typesmiths Pi Font

**CrossTech**  
 COMMUNICATIONS INC

312 382-0111  FAX 382-0004

03208 Rev. 1 6/05



astellas



3g

Gel, 5%  
(dapsona)

ACZONE™

5%

Black

PMS2756C

PMS265C

Astellas logo

Red: 193C

Gray Cool gray 9C

Overlap: 193C + Cool Gray 9C (40%)

101.6x76.2x50.8

ACZONE™  
(dapsona)  
Gel, 5%



Manufactured  
by QLT USA, Inc.,  
Fort Collins, CO 80525  
for Astellas Pharma US, Inc.,  
Deerfield, IL 60015-2548



5%

NDC 0469-5005-03

ACZONE™  
(dapsona)  
Gel, 5%

**FOR TOPICAL USE ONLY.**  
Not for oral, ophthalmic, or intravaginal use.  
**WARNING:** Keep out of the reach of children.  
**Rx only**


500503  
Each gram of ACZONE™ (dapsona) Gel, 5%,  
contains 50 mg of dapsona, USP, in a gel of  
carbomer 980, diethylene glycol monoethyl  
ether, NF; methylparaben, NF; sodium  
hydroxide, USP; and purified water, USP.


**Dosage:** Apply twice daily. See package insert  
for dosage information.

**Storage:** Store at controlled room temperature  
20°-25°C (68°-76°F), excursions permitted to  
15°-30°C (59°-86°F). **Protect from freezing.**


**For Lot and Exp.:** See crimp of tube.

PROFESSIONAL SAMPLES- NOT FOR SALE





- Red: Astellas Red (PMS 193C)
- Dark Red: Astellas Red+Astellas Gray (PMS 193C + Cool Gray 9C @40%)
- Gray: Astellas Gray (PMS Cool Gray 9C)
- Purple: PMS 265C
- Black



CrossTech-46870-Proof A9  
 Form M01  
 Astellas Pharma, US, Inc.-PO. 21321-Job No. 02109  
 6/30/05-am -Q4.1

Fonts: Helvetica (A)  
 Typesmiths Pi Font

GTIN (01)00304695005303

**CrossTech**  
**COMMUNICATIONS INC**

312 382-0111  FAX 382-0004



Black


PMS265C

Astellas logo

Red: 193C

Gray Cool gray 9C

Overlap: 193C + Cool Gray 9C (40%)





For Lot and Exp: See Top Flap.

Storage: Store at controlled room temperature 20°-25°C (68°-76°F), excursions permitted to 15°-30°C (59°-86°F).  
Protect from freezing and light. Return to the original carton after application.

ACZONE™  
(dapson)  
Gel, 5%

5%

NDC 0469-5005-30

ACZONE™  
(dapson)  
Gel, 5%



500530

5%



30g

5%

NDC 0469-5005-30

ACZONE™  
(dapson)  
Gel, 5%



500530

FOR TOPICAL USE ONLY. Not for oral, ophthalmic, or intravaginal use.  
WARNING: Keep out of the reach of children.  
Each gram of ACZONE™ (dapson) Gel, 5%, contains 50 mg of dapson, USP, in a gel of carbomer 980; diethylene glycol monoethyl ether, NF; methylparaben, NF; sodium hydroxide, USP; and purified water, USP.  
Dosage: Apply twice daily. See package insert for dosage information.

Rx only



(01) 2 0304695 00530 7

30g



5%

Black PMS265C  
Astellas logo  
Red: 193C  
Gray Cool gray 9C  
Overlap: 193C + Cool Gray 9C (40%)

NDC 0469-5005-30

ACZONE™  
(dapson)  
Gel, 5%



500530



30g

5%


03209 Rev. 1 6/05

ACZONE™  
(dapson)  
Gel, 5%



Storage: Store at controlled room temperature 20°-25°C (68°-76°F), excursions permitted to 15°-30°C (59°-86°F).  
Protect from freezing and light. Return to the original carton after application.

30g



CrossTech  
COMMUNICATIONS INC  
312.382.0111 FAX: 382.0004

CrossTech-46868-Proof A3  
Form M01  
Astellas Pharma US, Inc.-P.O. 21321-Job No. 03200  
Aczone Gel 5%  
6/30/05-am-Q4.11  
GTIN (01)2030469500530C

ACZONE™  
(dapson)  
Gel, 5%



Manufactured by QLT USA, Inc. Fort Collins, CO 80525 for Astellas Pharma US, Inc. Deerfield, IL 60015-2548

5%

30g

